PDS Biotechnology Reports Financial Results for the First Quarter 2020 and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
PDS Biotechnology (PDSB) Misses Q1 EPS by 24c
May 13, 2020 6:01 AM EDTPDS Biotechnology (NASDAQ: PDSB) reported Q1 EPS of ($0.39), $0.24 worse than the analyst estimate of ($0.15).
First Quarter 2020 and Recent Business Highlights
Initiated novel vaccine development programs for COVID-19 and universal influenza;Announced pre-clinical collaboration with Farmacore Biotechnology for tuberculosis;Delayed initiation of Phase 2 VERSATILE-002 trial for PDS0101 in recurrent/metastatic head and neck cancer due to the global COVID-19 pandemic;Secured the U.S. composition of matter patent for the Versamune® platform;Expanded... More


